Human glioblastoma in mouse

Publications

The following includes a selection of recent publications from our lab.

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.

Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H.

Front Immunol. 2019 Jan 22; 9: 3062. doi: 10.3389/fimmu.2018.03062.
PubMed Link >

Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas

Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G.

JCI Insight. 2018 Apr 5; 3 (7): 98791. doi: 10.1172/jci.insight.98791. [Epub ahead of print].
PubMed Link >

Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia, KC, Hou Y and Okada H.

J Exp Med. 2018 Jan 2; 215 (1): 141-157. doi: 10.1084/jem.20171046. Epub 2017 Dec 4.
PubMed Link >

Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment

Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A.

Genome Biol. 2017 Dec 20; 18 (1): 234. doi: 10.1186/s13059-017-1362-4.
PubMed Link >

Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model

Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET.

Sci Rep. 2017 Dec 18; 7 (1): 17748. doi: 10.1038/s41598-017-17669-4.
PubMed Link >

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY. 

Oncoimmunology. 2017 Nov 7; 7 (2): e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.
PubMed Link >

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19; 9 (399): eaaa0984. doi: 10.1126/scitranslmed.aaa0984.
PubMed Link >

Is the immune response a friend or foe for viral therapy of glioma?

Okada H, Thorne SH.

Neuro Oncol. 2017 Jul 1; 19 (7): 882-883. doi: 10.1093/neuonc/nox082.
PubMed Link >

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H.

J Clin Invest. 2017 Apr 3; 127 (4): 1425-1437. doi: 10.1172/JCI90644. Epub 2017 Mar 20.
PubMed Link >

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience

Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A.

Neuroimaging Clin N Am. 2017; 27 (1): 155-166. doi: 10.1016/j.nic.2016.09.002.
PubMed Link >

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. 

J Neurooncol. 2016; 130 (3): 517-527. Epub 2016 Sep 13.
PubMed Link >

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma

Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H.

J Neurooncol. 2016; 130 (3): 543-552. Epub 2016 Sep 13.
PubMed Link >

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression

Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N.

Neuro Oncol. 2016; 18 (10): 1402-12. doi: 10.1093/neuonc/now061. Epub 2016 Apr 25.
PubMed Link >

Cellular immunotherapy for malignant gliomas

Lin Y, Okada H.

Expert Opin Biol Ther. 2016; 16 (10): 1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29.
PubMed Link >

Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine

Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM.

Sci Rep. 2016 Aug 10; 6: 31397. doi: 10.1038/srep31397.
PubMed Link >